Stallergenes Greer: Alustal®, the Company’s Subcutaneous Allergen Immunotherapy Treatment (SCIT) Now Available
24.6.2021 14:17:00 EEST | Business Wire | Press release
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces that Alustal®, its subcutaneous allergen immunotherapy (SCIT) solution, is now available in Italy and Spain following the full resumption of SCIT production in Antony (France). Alustal® will be also available in Australia, France and Switzerland in the coming months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005500/en/
“We are pleased that patients and the medical community have access to an alternative allergen immunotherapy option with Alustal®. Stallergenes Greer’s comprehensive SCIT offering is the result of sustained investments in state-of-the-art manufacturing facilities and quality systems and reflects our commitment to offer a wide range of personalised treatment options which meet physicians’ needs for precision treatment” declares Amer Jaber, Executive VP Operations Europe & International.
Stallergenes Greer’s SCIT products meet the needs of patients whose profile and lifestyle require an alternative access to treatment and delivery mode, longer intervals between treatment, or monitoring of adherence by their physician. The company’s SCIT offering also includes Albey® which will be progressively reintroduced and Alyostal® prick tests.
Stallergenes Greer is committed to developing a wide portfolio of precise personalised treatment solutions tailored to each patient profile and to each market, including diagnostics, injectable therapies and sublingual therapies such as drops and tablets.
ABOUT ALUSTAL®
Alustal® is an aluminium-based suspension for subcutaneous injection launched in 1997.The aluminum adjuvant allows the slow release of antigen at the injection site to stimulate the immune response.
Alustal® is indicated for Type I allergies (Gell and Coombs classification) mainly involving rhinitis, conjunctivitis, rhinoconjunctivitis or asthma (mild to moderate), of a seasonal or perennial nature, in children, adolescents and adults.
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at https://www.stallergenesgreer.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005500/en/
Contact information
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio22.9.2026 15:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at EADV 2026 highlights the strength of our Inflammation and Autoimmunity portfolio," said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Data presentations in hidradenitis suppurativa, atopic dermatitis and prurigo nodularis demonstrate our commitment to advancing innovation across immune-mediated skin diseases and deepening our understanding of the patient experience." Details on key Incyte data presentations at EADV include: Oral Presentations Atopic Dermatitis Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL) (Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October 1, 2:50-3:0
Citi Wealth’s 2026 Global Family Office Report Reveals Clients Are Shifting Their Focus Towards Public Equities While Becoming More Deliberate and Resilient Amid Uncertainty22.9.2026 15:30:00 EEST | Press release
Citi Wealth today released its 2026 Global Family Office Report, offering an inside perspective into the thinking and behaviors of the world’s most sophisticated investors. The report was compiled by Citi Wealth’s Global Family Office Group, which works with more than 1,900 family offices worldwide. Conducted in June and July 2026, the survey sheds light on how over 350 family offices in more than 40 countries are navigating new complexities in an era defined by uncertainty. Today’s leading family offices are building long-term strategies underpinned by three key themes: capital, capability and continuity. They are investing with confidence -- becoming more institutional in how they invest, more sophisticated in how they manage risk, and more intentional in how they prepare for the future. Families also are prioritizing leadership succession and generational transition with new urgency. Key takeaways include: Strong Performance in the Face of Rising Uncertainty: Despite shifting macroe
Manhattan Associates Announces Editions™ for its Industry-Leading Solutions, Making Them Accessible at Every Stage of Growth22.9.2026 15:30:00 EEST | Press release
Manhattan Associates (NASDAQ: MANH), the global leader in supply chain commerce with unmatched AI capabilities, today announced the commercial launch of Editions for Manhattan Active® solutions. Editions provide a new way for companies of all sizes and across industries to partner with Manhattan. They are designed to help growing organizations make a durable, long-term technology decision from the start. As complexity increases, customers can unlock additional capabilities on the same platform, rather than starting over. Built for ActiveWarehouse™, ActiveTransportation™, ActiveStore™ and ActiveOrder™, on Manhattan’s award-winning ActivePlatform™, there are three Editions available: Essentials, Enterprise and Enterprise Premier. Regardless of the Edition selected for each solution, companies gain access to the power of a unified platform, AI capabilities and continuous innovation that underpin some of the world’s most complex supply chain and commerce operations. Editions are not separa
Elydan Acquieres Radpol Pipes in Poland Expanding Its Offering to Accelerate the Decarbonization of Europe's Energy Infrastructure22.9.2026 15:24:00 EEST | Press release
ELYDAN Group, specialist in water and energy network solutions, announces the acquisition of Radpol Pipes, a Polish industrial company specializing in the manufacture of pre-insulated piping systems for district heating and cooling networks. The acquisition expands Elydan’s capabilities in low-carbon energy infrastructure. The Group is entering a new phase of its European development with more than €250 million in revenue and 600 employees across 7 European countries. Expanding in Europe market driven by decarbonization and energy sovereignty “With Radpol Pipes, we are adding the technological expertise needed to cover the full range of district heating and cooling networks. This acquisition reflects a very concrete ambition: to provide our customers with the most comprehensive solutions to accelerate the decarbonization of infrastructure and contribute to Europe’s energy sovereignty. It is also a key milestone in our Momentum 2030 strategy, reinforcing our ambition to build a leading
ADX and Its Listed Companies Connect with International Capital at Global Investor Roadshow in New York22.9.2026 15:01:00 EEST | Press release
The Abu Dhabi Securities Exchange (ADX) Group is heading to New York for its annual Global Investor Roadshow and Conference, held in collaboration with Morgan Stanley on 24 and 25 September 2026. This is part of ADX’s ongoing commitment and engagement outreach to institutional investors across key global financial centers. The ADX event in New York will highlight the investment opportunities Abu Dhabi’s capital markets offer through its leading listed companies, as the ADX supports Abu Dhabi’s long-term economic vision and sustainable economic growth as a global capital hub. H.E. Ghannam Butti Almazrouei, Chairman of the ADX, and Abdulla Salem Alnuaimi, Group Chief Executive Officer, will lead the delegation. They will be joined by senior management and investor relations officers from 14 ADX-listed companies. Direct discussions with management teams will enable investors to explore company fundamentals, competitive positioning, and investment propositions in greater depth. The delegat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom